Our Clinical Services and Research
Our research centres on clinical metabolomics and clinical lipidomics, which comprise the large-scale, untargeted measurement of metabolites and lipids in the human body. We develop and apply these methods both as routine diagnostic tools and as discovery platforms to answer fundamental questions in human disease.
🏥 Clinical Services for Patients & Clinicians
If you are a clinician, specialist, or patient with questions about whether metabolomic or lipidomic analysis could be relevant for a clinical case, we are here to help.
What we offer
- Global metabolomics analysis of blood, urine, plasma, dried blood spots, and other body fluids
- Global lipidomics profiling
- Analysis in support of the diagnosis of inborn errors of metabolism
- Consultations on whether metabolomics could be relevant for your patient or clinical question
Referrals are made through the Oslo University Hospital. Clinicians with specific questions are welcome to contact us directly.
Research Focus Areas
Clinical Metabolomics
We use liquid chromatography coupled to high-resolution mass spectrometry (LC-Orbitrap MS) to measure thousands of metabolites simultaneously in blood, urine, plasma, dried blood spots, tear fluid, bile, and cerebrospinal fluid. This untargeted approach captures both known and unknown compounds — revealing the molecular fingerprint of disease without pre-selecting what to look for.
Clinical Lipidomics
Lipids play central roles in cell structure, signalling, and energy metabolism. Our global lipidomics platform provides comprehensive lipid profiling, enabling us to study how lipid metabolism is altered in disease and how it responds to treatment.
Inborn Errors of Metabolism (IEM)
A major research focus is inherited metabolic diseases — rare genetic conditions that disrupt normal metabolic pathways. We apply our metabolomics platform to improve diagnosis, understand disease mechanisms, and monitor treatment outcomes. Our national laboratory for IEM diagnosis is based at Oslo University Hospital – Rikshospitalet.
Biomarker Discovery & Clinical Translation
We actively collaborate with clinical specialists across a broad range of disease areas — including oncology, ophthalmology, infectious disease, and cardiovascular medicine — to identify and validate metabolic and lipidomic biomarkers with diagnostic and prognostic potential.
Method Development
Improving analytical methods is a continuous priority. Our team develops and validates new workflows for sample preparation, data acquisition, and bioinformatic processing — ensuring our platform remains at the forefront of clinical metabolomics.
Instruments & Technology
Our laboratory is equipped with two state-of-the-art LC-HRMS systems:
- Dionex Ultimate 3000 HPLC – Q Exactive Orbitrap
- Vanquish Horizon HPLC – Orbitrap Fusion Tribrid
Our in-house compound library currently covers approximately 1,000 identified metabolites and lipids, with continuous expansion.
Key Collaborations
- Oncology (pancreatic cancer, serum lipidomics)
- Ophthalmology (dry eye disease, tear fluid metabolomics)
- Infectious disease and sepsis (host metabolic response)
- Neurodevelopmental disorders and genetics
- Cardiovascular and rheumatological disease